NUNZIA PHARMACEUTICAL COMPANY |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.003 USD | -.--% |
|
-.--% | -.--% |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Capitalization 1 | 0.3582 | 0.3511 | 0.1966 | 733.1 | 169.8 |
| Enterprise Value (EV) 1 | 0.3812 | 0.3741 | 0.1966 | 733.1 | 169.9 |
| P/E ratio | -28.1 x | -19.4 x | -81,612 x | -94.8 x | -2.54 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | -1.33 x | -1.22 x | -197,352 x | -20,270 x | -3,010 x |
| Nbr of stocks (in thousands) | 20.5 | 20.5 | 18.1 | 244,370 | 261,120 |
| Reference price 2 | 17.51 | 17.16 | 10.85 | 3.000 | 0.6501 |
| Announcement Date | 31/05/19 | 31/05/19 | 16/09/21 | 16/09/21 | 15/04/22 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Net sales | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -0.013 | -0.0272 | -0.0336 | -0.0163 | -78.06 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.013 | -0.0186 | -0.0336 | -9.016 | -78.06 |
| Net income 1 | -0.013 | -0.0186 | -0.0336 | -9.016 | -78.06 |
| Net margin | - | - | - | - | - |
| EPS 2 | -0.6220 | -0.8858 | -0.000133 | -0.0316 | -0.2556 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 31/05/19 | 31/05/19 | 16/09/21 | 16/09/21 | 15/04/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Net Debt 1 | 0.02 | 0.02 | - | - | 0.1 |
| Net Cash position 1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 6.53% | 21.3% | 30,575% | 101,659% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | -13.10 | -14.00 | -0 | -0 | -0 |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 31/05/19 | 31/05/19 | 16/09/21 | 16/09/21 | 15/04/22 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 1.3M | |
| +32.77% | 698B | |
| +26.51% | 568B | |
| -4.55% | 358B | |
| +19.54% | 328B | |
| +3.51% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +9.11% | 165B |
- Stock Market
- Equities
- NUNZ Stock
- Financials Nunzia Pharmaceutical Company
